Science Daily21h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Cochrane1d
Does treatment with GLP-1 receptor agonists prevent complications for people with chronic kidney disease and diabetes?
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
Healio1d
Few hospitalized adults with type 2 diabetes prescribed SGLT2, GLP-1 medication
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
Lexicon’s sotagliflozin shows cardiovascular efficacy in published study
Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...
Heart Failure Deaths Are Increasing. New Treatments Could Help.
The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...
‘First of its kind’ medication can significantly reduce heart attacks and strokes
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
BMJ14d
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
126.com Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been ... by reducing proteinuria and ameliorating progressive renal failure in ...
Everyday Health on MSN15d
The Best Medication for Diabetes May Depend on Age
A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...
MedPage Today16d
Heart Protection With SGLT2, GLP-1 Drugs for Diabetes Mediated by Age
Opens in a new tab or window SGLT2 inhibitors were more cardioprotective ... Data on additional outcomes like end-stage kidney disease, heart failure, and medication-related harms weren't assessed.
Frontiers16d
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction ... GLP-1 receptor agonists, SGLT2 inhibitors, and metformin. NAFLD, non-alcoholic ...
Endocrinology Advisor16d
SGLT2 Inhibitor Use May Help Prevent Kidney Stones in Patients Without Diabetes
They added that “it seems very likely that SGLT2 inhibitors will also result in a substantial reduction in recurrent stone events in patients with pure [calcium oxalate] stones.” Despite the concern ...
ExtremeTech17d
How Do SSDs Work? The Inner Details, Explained
The reason TLC NAND is slower than MLC or SLC has to do with how data moves in and out ... as performing some of the same load-balancing work as a high-end storage array—SSDs don't deploy ...